C1-Inhibitor
ApprovedSmall molecule
C1-Inhibitor is one of 80 small molecule programs targeting Ischemia. It is currently in Approved.
2
Indications
3
Total Trials
0
Active Trials
79
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
159 competitors in Ischemia
#DrugCompanyPhaseTrials
1Adenocard
AstellasPhase 3
Isordil
AstraZenecaPhase 3
Osmitrol
BB. Braun Medical Inc.
Phase 3
Cardizem
BBausch Health Americas, Inc.
Phase 3
Flagyl
DDePuy Orthopaedics
Phase 3
Garamycin
SSchering-Plough
Phase 3
Procardia
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Avlosulfon
AAlmirall, S.A.
Phase 3
Remodulin
United TherapeuticsPhase 3
C1-Inhibitor
UUniversitaire Ziekenhuizen KU Leuven
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for C1-Inhibitor. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details